Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?

Johnson's Invokana is about to face a host of new SGLT2 competitors from AstraZeneca, Merck, and Eli Lilly.

Apr 21, 2014 at 8:44AM

The market for diabetes treatment has never been bigger, and that is propelling sales of Johnson & Johnson's (NYSE:JNJ) Invokana higher.

According to data from Express Scripts, the nation spent 14% more on diabetes drugs in 2013 than it did in 2012. A major reason for that jump is a new wave of therapies, including Invokana, that are designed to improve how the body eliminates glucose. Since Invokana helped lift Johnson's first-quarter sales in the U.S. last quarter, let's look at its potential for the rest of 2014.

JNJ Chart

JNJ data by YCharts.

Big market getting bigger
Unfortunately, some 70 million people in developed regions, including North America and Europe, have been diagnosed with diabetes, and 38% of patients fail to properly take their current medication. As a result, the need for new, game-changing diabetes therapies is big.

As large as the market is, it's only getting bigger. Express Scripts expects spending on diabetes treatment will grow 11% in 2014, 12% in 2015, and 10% in 2016. But those increases only hint at long-term spending. After all, the global patient population of diabetics is expected to grow from 365 million people today to 550 million people by 2030.

Given the need for therapies and the size of that market, drugmakers such as Johnson & Johnson have been hard at work developing next-generation drugs like Invokana, the first in a new class of diabetes drugs to win FDA approval.

Invokana targets the SGLT2 protein in the kidney that aids in the reabsorption of glucose. Since Invokana blocks the kidney's ability to reabsorb glucose, it helps blood glucose levels fall by allowing more of it to be eliminated through patients' urine.

Since Invokana was the first SGLT2 inhibitor approved by the FDA, it has a first-to-market advantage that is enabling it to capture market share. While J&J doesn't break out sales of Invokana yet, the company's "other" drug sales, within includes Invokana, posted nearly 15% growth in the first quarter, reaching nearly $300 million.

Although Johnson & Johnson did not share much Invokana sales data in its first-quarter earnings press release, the company did give investors more insight during its conference call.

In the first quarter, Invokana contributed 2.5% to Johnson & Johnson's U.S. growth rate, and captured a bit more than 2% prescription market share in type 2 patients, excluding prescriptions for insulin and metformin. That market share was up from 1.5% in the fourth quarter.

Competition is coming
While Invokana cut the path as the first SGLT2 inhibitor, others are following behind. AstraZeneca (NYSE:AZN) won FDA approval for its SGLT2 drug, Farxiga, in January.

AstraZeneca purchased the half of its diabetes partnership it didn't own from Bristol-Myers Squibb in December. Farxiga joins a diabetes lineup that already featured GLP-1 drugs Byetta and Bydureon too. While it remains to be seen if Farxiga can steal market share from Invokana, analysts think the drug's peak sales could eclipse the $1 billion blockbuster mark.

Merck (NYSE:MRK) and Pfizer are developing their own SGLT2 inhibitor, ertugliflozin. Ertugliflozin is in phase 3 trials; if approved, it would join Merck's already dominant diabetes blockbuster Januvia in the company's product lineup, and Merck will capture 60% of the drug's profits.

Not to be left out, Eli Lilly (NYSE:LLY), the maker of the widely used blockbuster insulin Humalog, hopes to soon sell its own SGLT2 inhibitor, empagliflozin.

Lilly is co-developing that drug with Boehringer Ingelheim; in studies, using the drug alongside insulin significantly cut glucose levels versus insulin alone. 

Despite those solid trial results, the FDA issued the two companies a rejection letter in March, citing concerns with one of Boehringer's manufacturing plants. However, the EU seems less concerned with that plant, and its advisory Committee for Medicinal Products for Human Use recommended the drug's approval just of couple weeks later.

Despite the speed bump, the two companies this month returned to the FDA with a new application for a regimen combining empagliflozin with a DPP-4 inhibitor, which stimulates insulin production in the pancreas.

Fool-worthy final thoughts
Industry watchers think Johnson & Johnson's Invokana could eventually achieve peak sales of more than $2 billion. While that could prove correct, for now investors will have to see whether the growing market will support more than one SGLT2 drug. That means J&J''s investors should pay attention to results from competitors AstraZeneca, Merck, and Lilly this year.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers